Mylan files ANDA for generic APONVIE; Heron to defend 10 patents

HERON THERAPEUTICS, INC. /DE/

Mylan filed paragraph IV certification notice for generic version of APONVIE (aprepitant).
Heron will file patent infringement lawsuit within 45 days of December 18, 2023 notice.
10 Orange Book-listed patents expiring September 18, 2035 are challenged as invalid or not infringed.
FDA approval of Mylan's ANDA stayed for 7.5 years if suit is timely filed, absent court ruling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.